rolipram has been researched along with MS (Multiple Sclerosis) in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vesnarinone (OPC-8212) is a synthetic quinolinone derivative with inotropic and immunomodulatory effects." | 5.30 | The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis. ( Bergey, G; Bielekova, B; Clarence-Smith, K; Dhib-Jalbut, S; Jiang, H; Johnson, KP; Martin, R; Okazaki, H, 1999) |
| "Multiple sclerosis is an unmet disease in which pathologies on the immune system, T-cells, and specific neural cells are involved simultaneously." | 1.38 | Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. ( Alonso-Gil, S; Brea, J; Cadavid, MI; Campillo, NE; Gil, C; Loza, MI; Martin-Alvarez, R; Martinez, A; Mengod, G; Morales-García, JA; Paul-Fernandez, N; Perez, C; Perez, DI; Perez-Castillo, A; Redondo, M; Soteras, I; Val, C, 2012) |
| "Using Lewis rats with experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, we recently found a decrease in cannabinoid CB1 receptors mainly circumscribed to the basal ganglia, which could be related to the motor disturbances characteristic of these rats." | 1.33 | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. ( Cabranes, A; de Lago, E; Di Marzo, V; Fernández-Ruiz, J; Fezza, F; García-Merino, A; Mestre, L; Ramos, JA; Sánchez, A; Valenti, M; Venderova, K, 2005) |
| "Vesnarinone (OPC-8212) is a synthetic quinolinone derivative with inotropic and immunomodulatory effects." | 1.30 | The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis. ( Bergey, G; Bielekova, B; Clarence-Smith, K; Dhib-Jalbut, S; Jiang, H; Johnson, KP; Martin, R; Okazaki, H, 1999) |
| "Rolipram has extensively been studied in humans for the treatment of depression, but has not yet been marketed." | 1.29 | The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. ( Fontana, A; Lichtenfels, R; Löschmann, PA; Meyermann, R; Northoff, GH; Riethmüller, A; Sommer, N; Steinbach, JP; Steinbrecher, A; Weller, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Redondo, M | 1 |
| Brea, J | 1 |
| Perez, DI | 1 |
| Soteras, I | 1 |
| Val, C | 1 |
| Perez, C | 1 |
| Morales-García, JA | 1 |
| Alonso-Gil, S | 1 |
| Paul-Fernandez, N | 1 |
| Martin-Alvarez, R | 1 |
| Cadavid, MI | 1 |
| Loza, MI | 1 |
| Perez-Castillo, A | 1 |
| Mengod, G | 1 |
| Campillo, NE | 1 |
| Martinez, A | 1 |
| Gil, C | 1 |
| Sunke, R | 1 |
| Bankala, R | 1 |
| Thirupataiah, B | 1 |
| Ramarao, EVVS | 1 |
| Kumar, JS | 1 |
| Doss, HM | 1 |
| Medishetti, R | 1 |
| Kulkarni, P | 1 |
| Kapavarapu, RK | 1 |
| Rasool, M | 1 |
| Mudgal, J | 1 |
| Mathew, JE | 1 |
| Shenoy, GG | 1 |
| Parsa, KVL | 1 |
| Pal, M | 1 |
| Bielekova, B | 3 |
| Richert, N | 1 |
| Howard, T | 1 |
| Packer, AN | 1 |
| Blevins, G | 1 |
| Ohayon, J | 1 |
| McFarland, HF | 2 |
| Stürzebecher, CS | 1 |
| Martin, R | 4 |
| Cabranes, A | 1 |
| Venderova, K | 1 |
| de Lago, E | 1 |
| Fezza, F | 1 |
| Sánchez, A | 1 |
| Mestre, L | 1 |
| Valenti, M | 1 |
| García-Merino, A | 1 |
| Ramos, JA | 1 |
| Di Marzo, V | 1 |
| Fernández-Ruiz, J | 1 |
| Moore, CS | 1 |
| Earl, N | 1 |
| Frenette, R | 1 |
| Styhler, A | 1 |
| Mancini, JA | 1 |
| Nicholson, DW | 1 |
| Hebb, AL | 1 |
| Owens, T | 1 |
| Robertson, GS | 1 |
| Raine, CS | 1 |
| Sommer, N | 1 |
| Löschmann, PA | 1 |
| Northoff, GH | 1 |
| Weller, M | 1 |
| Steinbrecher, A | 1 |
| Steinbach, JP | 1 |
| Lichtenfels, R | 1 |
| Meyermann, R | 1 |
| Riethmüller, A | 1 |
| Fontana, A | 1 |
| Yoshikawa, M | 1 |
| Suzumura, A | 1 |
| Tamaru, T | 1 |
| Takayanagi, T | 1 |
| Sawada, M | 1 |
| Jiang, H | 1 |
| Okazaki, H | 1 |
| Clarence-Smith, K | 1 |
| Johnson, KP | 1 |
| Bergey, G | 1 |
| Dhib-Jalbut, S | 1 |
| Pette, M | 1 |
| Muraro, PA | 1 |
| Pette, DF | 1 |
| Dinter, H | 1 |
| Lincoln, A | 1 |
| McFarland, H | 1 |
| 't Hart, BA | 1 |
| van Meurs, M | 1 |
| Brok, HP | 1 |
| Massacesi, L | 1 |
| Bauer, J | 1 |
| Boon, L | 1 |
| Bontrop, RE | 1 |
| Laman, JD | 1 |
| Agnello, D | 1 |
| Carvelli, L | 1 |
| Muzio, V | 1 |
| Villa, P | 1 |
| Bottazzi, B | 1 |
| Polentarutti, N | 1 |
| Mennini, T | 1 |
| Mantovani, A | 1 |
| Ghezzi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis[NCT05080270] | Early Phase 1 | 5 participants (Actual) | Interventional | 2020-09-21 | Completed | ||
| Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure[NCT00011375] | Phase 2 | 52 participants | Interventional | 2001-02-28 | Completed | ||
| Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients[NCT02489877] | 84 participants (Anticipated) | Observational | 2015-07-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for rolipram and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Multiple sclerosis: TNF revisited, with promise.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Sclerosis; Phosphodiesterase | 1995 |
1 trial available for rolipram and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.
Topics: Biomarkers; Blood-Brain Barrier; Cell Proliferation; Contrast Media; Humans; Immunophenotyping; Infl | 2009 |
11 other studies available for rolipram and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Cell Survival; Cyclic AMP; Cy | 2012 |
InCl
Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Exp | 2019 |
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arachidonic Acids; Basal Ganglia; Brain; Cannabinoid R | 2005 |
Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Weight; Cyclic Nucleotide Phosphodiesterases, Typ | 2006 |
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
Topics: Animals; Antidepressive Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Encephalomyelitis, Auto | 1995 |
Effects of phosphodiesterase inhibitors on cytokine production by microglia.
Topics: 1-Methyl-3-isobutylxanthine; Amrinone; Animals; Anti-Ulcer Agents; Cilostazol; Colforsin; Dipyridamo | 1999 |
The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Viral; Cell Division; Cel | 1999 |
Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 8-Bromo Cyclic Adenosine Monophosphate; Antibodies; Autoantigen | 1999 |
Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adjuvants, Immunologic; Amino Acid Sequence; Autoantigens; B7-1 | 2000 |
A new primate model for multiple sclerosis in the common marmoset.
Topics: Acute Disease; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Callithrix; CD40 Antigens; Cebi | 2000 |
Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Binding Sites; C-Reactive Protein; Dexamethasone; E | 2000 |